LONDON (Alliance News) - Midatech Pharma PLC Wednesday said its 2015 revenue will be "slightly ahead of expectations" following its recent acquisitions of Dara BioSciences and Zuplenz, and it also forecast revenue growth at the higher end of market forecasts for 2016.
"Following the acquisition of DARA BioSciences and Zuplenz, and further licensing and supply agreements, 2015 has shown significant growth for Midatech, achieving the strategic objectives set out at the time of the IPO and accelerating the company towards sustainable profitability," said Chief Executive Officer Jim Phillips in a statement.
"With an established commercial operation in the US, we expect to deliver strong revenue growth in 2016 at the higher end of current market expectations as we reinforce our position as an oncology-focussed specialty pharmaceutical company," Phillips added.
Midatech expects to report its 2015 results in April.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
